Patents by Inventor Dorothee Andres

Dorothee Andres has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified lipopolysaccharide glycoform and method of use
    Patent number: 10864266
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Grant
    Filed: November 21, 2019
    Date of Patent: December 15, 2020
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres
  • Macrocyclic sulfondiimine compounds
    Patent number: 10717749
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 26, 2016
    Date of Patent: July 21, 2020
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Jens Geisler, Daniel Hog, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Kunzeng Zheng, Ping Gao, Gang Chen, Jiajun Xi, Simon Anthony Herbert, Gerhard Siemeister, Nicolas Werbeck
  • MODIFIED LIPOPOLYSACCHARIDE GLYCOFORM AND METHOD OF USE
    Publication number: 20200121786
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Application
    Filed: November 21, 2019
    Publication date: April 23, 2020
    Applicants: The Trustees of Princeton University, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres
  • Modified lipopolysaccharide glycoform and method of use
    Patent number: 10525126
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: January 7, 2020
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres
  • Modified macrocyclic compounds
    Patent number: 10214542
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: February 26, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich Lücking, Daniel Hog, Jens Geisler, Arne Scholz, Kirstin Petersen, Philip Lienau, Christian Stegmann, Dorothee Andres, Gerhard Siemeister, Nicolas Werbeck
  • NOVEL MODIFIED MACROCYCLIC COMPOUNDS
    Publication number: 20180282346
    Abstract: The present invention relates to novel modified macrocyclic compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 30, 2016
    Publication date: October 4, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Daniel HOG, Jens GEISLER, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Gerhard SIEMEISTER, Nicolas WERBECK
  • NOVEL MACROCYCLIC SULFONDIIMINE COMPOUNDS
    Publication number: 20180273548
    Abstract: The present invention relates to novel macrocyclic sulfondiimine compounds of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).
    Type: Application
    Filed: September 26, 2016
    Publication date: September 27, 2018
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Ulrich LÜCKING, Jens GEISLER, Daniel HOG, Arne SCHOLZ, Kirstin PETERSEN, Philip LIENAU, Christian STEGMANN, Dorothee ANDRES, Kunzeng ZHENG, Ping GAO, Gang CHEN, Jiajun XI, Simon Anthony HERBERT, Gerhard SIEMEISTER, Nicolas WERBECK
  • MODIFIED LIPOPOLYSACCHARIDE GLYCOFORM AND METHOD OF USE
    Publication number: 20170239350
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 24, 2017
    Applicant: The Trustees of Princeton University
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres
  • Modified lipopolysaccharide glycoform and method of use
    Patent number: 9677052
    Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: June 13, 2017
    Assignee: THE TRUSTEES OF PRINCETON UNIVERSITY
    Inventors: Thomas J. Silhavy, Marcin Grabowicz, Daniel Kahne, Matthew Lebar, Dorothee Andres